2EKBOM A.The epidemiology of IBD:a lot of data but little knowledge.How shall we proceed?[J].Inflamm Bowel Dis,2004,10 Suppl 1:S32-34.
3BICKSTON SJ,COMERFORD LW,COMINELLIF.Future therapies for inflammatory bowel disease[J].Curt Gastroenterol Rep,2003,5(6):518-523.
4SARTOR RB.Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases:antibiotics,probiotics,and prebiotics[J].Gastroenterology,2004,126(6):1620-1633.
5PAVAN S,DESREUMAUX P,MERCENIER A.Use of mouse models to evaluate the persistence,safety,and immune modulation capacities of lactic acid bacteria[J].Clin Diagn Lab Immunol,2003,10(4):696-701.
6LINSKENS RK,HUHSDENS XW,SAVELKOUL PH,et al.The bacterial flora in inflammatory bowel disease:current insights in pathogenesis and the influence of antibiotics and probiotics[J].Scand J Gastroenterol Suppl,2001,(234):29-40.
7SYDORA BC,TAVERNINI MM,WESSLER A,et al.Lack of interleukin-10 leads to intestinal inflammation,independent of the time at which luminal microbial colonization occurs[J].Inflamm Bowel Dis,2003,9(2):87-97.
8FARRELL RJ,LAMONT JT.Microbial factors in inflammatory bowel disease[J].Gastroenterol Clin North Am,2002,31(1):41-62.
9KWEON M,TAKAHASHI I,KIYONO H.New insights into mechanism of inflammatory and allergic diseases in mucosal tissues[J].Digestion,2001,63 Suppt 1:1-11.
10NIELSON OH,VAINER B,MADSEN SM,et al.Established and emerging biological activity markers of inflammatory bowel diseas[J].Am J Gastroenterol,2000,95(2):359-367.
